These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28253394)

  • 1. Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.
    Goyal G; Shah MV; Call TG; Litzow MR; Hogan WJ; Go RS
    JAMA Oncol; 2017 Sep; 3(9):1253-1256. PubMed ID: 28253394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PET-CT documented complete remission of Erdheim-Chester disease, lasting more than 4 years from treatment initiation with cladribine].
    Adam Z; Řehák Z; Koukalová R; Bortlíček Z; Krejčí M; Pour L; Szturz P; Prášek J; Nebeský T; Adamová Z; Král Z; Mayer J
    Vnitr Lek; 2014; 60(5-6):499, 501-11. PubMed ID: 24974755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
    Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
    Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
    Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
    BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature].
    Adam Z; Petrášová H; Řehák Z; Koukalová R; Krejčí M; Pour L; Vetešníková E; Čermák A; Ševčíková S; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2016; 62(10):820-832. PubMed ID: 27900869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of 3 patients with Erdhiem-Chester disease with cladribin or cladribin in combination with cyclophosphamide. Case report and review of the therapy].
    Král Z; Řehák Z; Krejčí M; Koukalová R; Ševčíková S; Pour L; Krejčí M; Štork M; Sandecká V; Adam Z
    Vnitr Lek; 2021; 67(3):157-164. PubMed ID: 34171955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.
    Bhatia A; Hatzoglou V; Ulaner G; Rampal R; Hyman DM; Abdel-Wahab O; Durham BH; Dogan A; Ozkaya N; Yabe M; Petrova-Drus K; Panageas KS; Reiner A; Rosenblum M; Diamond EL
    Neuro Oncol; 2020 Jul; 22(7):979-992. PubMed ID: 31950179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
    Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
    [No Abstract]   [Full Text] [Related]  

  • 12. [Erdheim-Chester disease: an aggressive systemic disease treated with cladribine with favorable outcome (a case report)].
    Lasri N; Lahlimi F; Tazi MI
    Pan Afr Med J; 2022; 42():32. PubMed ID: 35910054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report.
    Tamura S; Kawamoto K; Miyoshi H; Suzuki T; Katagiri T; Kasami T; Nemoto H; Miyakoshi S; Kobayashi H; Shibasaki Y; Masuko M; Takeuchi K; Ohshima K; Sone H; Takizawa J
    J Clin Exp Hematop; 2018 Dec; 58(4):161-165. PubMed ID: 30305475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review].
    Adam Z; Koukalová R; Sprláková A; Rehák Z; Cervinek L; Szturz P; Krejcí M; Pour L; Zahradová L; Moulis M; Prásek J; Chaloupka R; Hájek R; Mayer J
    Vnitr Lek; 2011 Jun; 57(6):576-89. PubMed ID: 21751544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erdheim-Chester Disease: a comprehensive review of the literature.
    Mazor RD; Manevich-Mazor M; Shoenfeld Y
    Orphanet J Rare Dis; 2013 Sep; 8():137. PubMed ID: 24011030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
    Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
    Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns and organ treatment response of Erdheim-Chester disease with cardiac involvement.
    Miao HL; Chang L; Lin H; Liu ZZ; Wu W; Niu N; Cao XX
    Heart; 2024 Jun; 110(13):899-907. PubMed ID: 38772574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Hypothyroidism in Patients With Erdheim-Chester Disease.
    Shekhar S; Sinaii N; Irizarry-Caro JA; Gahl WA; Estrada-Veras JI; Dave R; Papadakis GZ; Tirosh A; Abel BS; Klubo-Gwiezdzinska J; Skarulis MC; Gochuico BR; O'Brien K; Hannah-Shmouni F
    JAMA Netw Open; 2020 Oct; 3(10):e2019169. PubMed ID: 33119105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME; Raderer M
    Hematol Oncol; 2017 Jun; 35(2):177-186. PubMed ID: 26580149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.